• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    High Drug Loading Amorphous Solid Dispersions

    Parenteral Drug Delivery Trends

    Selecting the Right Outsourcing Model for Emerging Biotech

    Inhaled Drug Delivery Technology

    The Future of Biologics: Accelerating Production, Reducing Costs
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    J&J’s Single-Dose COVID-19 Vax Issued EUA

    Icon to Acquire PRA Health Sciences

    Phlow Corp. and USP Form Alliance

    BMS Expands Cell Therapy Manufacturing Capabilities

    Novo Nordisk Invests $80M in Tablet Production
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    BMS Expands Cell Therapy Manufacturing Capabilities

    Novo Nordisk Invests $80M in Tablet Production

    Arcline Investment Acquires ChargePoint Technology

    Solid Dose Market Trends

    CatSci Opens New Site in UK
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Reshaping the Pharmaceutical Supply Chain

    Covectra Introduces Next-Gen Serialization Solution

    Bormioli Opens New Glass Research Center

    Centrient Pharmaceuticals to Acquire Astral SteriTech

    Seasonal Vaccine Manufacturing
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Icon to Acquire PRA Health Sciences

    BMS Expands Cell Therapy Manufacturing Capabilities

    Ashfield Engage, Popit Form Digital Monitoring Collaboration

    AMRI Contributes to Efforts to Increase COVID-19 Vax Supply

    CatSci Opens New Site in UK
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Guide to Maintaining Validation of Older Facilities: Why, When and How

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Alcami

    Reed-Lane

    Cytovance Biologics

    Flow Sciences

    Aphena Pharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    PCI Pharma Services

    Emergent BioSolutions

    Baxter BioPharma Solutions

    Adare Pharma Solutions

    Flow Sciences
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Pharma Beat

    Is Nicotine Such a ‘Bad Boy’?

    Investigating this controversial compound’s potential health benefits

    Related CONTENT
    • Mogene
    • Tackling TB Resistance
    • InSphero, Pfizer to Develop Assays for DILI
    • Could Nuts Ward Off Cancer?
    • The Trials and Tribulations of Male Contraception
    Adele Graham-King, Contributing Editor11.09.16
    We’re all acutely aware of the dangers that are associated with smoking and nicotine, and as such, nicotine has been branded the ‘bad boy’ of smoking for a long, long time. More recently the debate about e-cigarettes burns rapidly amongst health professionals and researchers as to the potential detrimental effects on health. But there are often questions asked about the potential health benefits of nicotine versus the risks associated with its inhalation during smoking, and this has attracted much attention and research over the past 30 years.

    Nicotine a is naturally occurring parasympathetic stimulant, which is found in plants of the nightshade family and various other plant leaves including Nicotiana tabacum, which is used in the manufacture of tobacco. Acting as a nicotinic acetylcholine receptor agonist nicotine is recognized as being highly addictive, and has a stimulatory effect in humans, impacting the cardiovascular system, respiratory system and central nervous system. Importantly, humans and mammals in general, develop tolerances to nicotine, which is one of the reasons why it is thought to be so addictive.

    Although it is absolutely categorically proven that smokers are at a massively increased risk of developing both lung and oral cancers and other pulmonary diseases, at the same time smokers do seem to have a reduced risk of certain other diseases such as the neurodegenerative disorder Parkinsons Disease. Non-smokers are at least three times more likely to die of this than nicotine puffing smokers—interesting, but yet maybe not necessarily surprising.

    The widespread physiological effect of nicotine is one of the reasons researchers suggest that it could indeed have medicinal uses outside of the psycho-stimulatory effect of euphoria and relaxation/stress reduction that many smokers associate with it. That’s not to say that nicotine in high doses isn’t dangerous. It is, and the U.S. Center for Disease Control still labels the chemical compound as a toxic chemical, but yet it’s not clearly established if it’s possible to pharmacologically harness any health benefits of the drug.

    Merely by its mode of action, nicotine is known to stimulate the release of many neurotransmitters and one of these is endorphins. Endorphins act in a similar manner to morphine and naturally impact the perception of human pain and modulate its pathway. Endorphins may also be involved in creating feelings of euphoria, which can be equally associated with nicotine use. The evidence for this particular physiological response to nicotine is well documented and the pathway understood, lending weight to the potential of nicotine in pain management.

    Maybe less well documented and acknowledged is the effect that nicotine may have on vasculature and revascularization. However, in 2000 a group of Stanford scientists accidentally discovered that nicotine, rather than damaging blood vessels, which is what they initially set out to prove, may actually stimulates the growth of new blood vessels, thus increasing and improving circulation. Ulceration is common in diabetic patients due to various factors including hyperglycemia, neuropathy and atherosclerosis. Left untreated ulceration may result in gangrene and limb amputation, having a huge impact on morbidity and mortality of patients. One of the outcomes of this discovery was the development of a nicotine-based topical gel, which has been investigated for its effect on diabetic ulcers. The nicotine-based compound, Targacept, which was being investigated by San Francisco-based CoMentis, entered into human trials in 2007 but in mid-2015 the product was dropped due to not reaching its primary end-point in Stage I/II trials, and consequently heard of no more.

    Another area of interest for nicotine is in the area of neurological disorders. There are plenty of theories that the little compound could be beneficial in conditions such as Parkinsons Disease (PD) and Alzheimers Disease (AD). Management of PD with the use of nicotine has been investigated since the mid-late 1960s when Harold Khan, an epidemiologist at the National Institute of Health noticed a misnomer in the prevalence of PD in smokers compared to non-smokers. His theory was that as nicotine stimulates the release of dopamine in the brain, the neurotransmitter, which seems to be less abundant in Parkinsons, and the chemical may well be an effective substitute in stimulating release.

    The Michael J. Fox Foundation initiated the first human clinical trial with the use of nicotine for treatment of PD several years ago in 2013. This double-blind trial has recruited over 150 PD patients randomized to either a nicotine patch (15mg) or placebo and is expected to deliver results by the end of 2016. A similar pilot study published by the University of Vermont in 2012 indicated that mild cognitive impairment (MCI) could be positively impacted also by application of a 15mg transdermal patch of nicotine on a daily basis. Many sufferers of the condition already self-treat, rightly or wrongly, with nicotine products. Sometimes, as we say, the proof is in the pudding.

    In a similar vein, Alzheimers is thought to be another area where nicotine may prevent, delay or alleviate symptoms. This is thought to be due to a combination of stimulation of production of acetylcholine and glutamine, both having a positive effect on memory, cognition and learning. In 2012 a small research study published in the journal Neurology investigated the same level of 15mg nicotine on long-term memory tests in Alzheimers sufferers and suggested a very similar effect that has been reported in previous investigations.
    It remains important however to understand the pharmacology of the action of nicotine in order to move forwards and develop these potential therapies, and many animal models have been investigated. Interestingly the University of Texas has very recently published results on the effect that nicotine has upon appetite in animal models and suggest that this may well be an indication of its ability to protect and modulate the synaptic responses in the brain.

    Researchers at the Texas A&M College of Medicine have investigated the effect that feeding animals low and medium concentrations versus high concentrations of nicotine-loaded drinking water has had on their feeding habits. The output of the research is that the lower and medium levels of nicotine water seemed to have no effect on weight gain, food intake and receptors in the brain; however the higher group elicited lower food intake, reduced weight gain and an increased number of receptors. Bearing in mind that appetite is physiologically influenced by hormones and neurotransmitters, is nicotine able to ‘bend the brain’ to influence eating behavior? Could this influence extend to more complex behaviors?

    Nicotine seems to have a wealth of evidence behind it from a pharmacological point of view in terms of benefitting—not treating—a lot of pathologies. Yet still there are no FDA approved nicotine treatments for alleviation of any diseases currently on the market. For smoking cessation, yes, but not for any of the above outlined conditions. Maybe we’ve tarred our own brush because the carcinogenic relationship with nicotine is ingrained in so many minds that we’re missing a great opportunity on a readily available compound for Pharma. The risk benefits of e-cigarettes aren’t clearly outlined yet either. For a chemical compound that’s been around for so long it’s an interesting conundrum that no line has been drawn around its benefits but lots of ‘wooly’ research is ongoing looking for proof that nicotine could help many people.

    What needs to remain clear is that smoking kills, and that puffing away isn’t the solution to the problem. But it would be amazing if something pharmacologically good could come out of the bad and prove to be an amazing, easily available, cheap therapy for these conditions. Maybe it’s time to give this ‘bad boy’ a chance?


    Adele Graham-King
    Contributing Editor

    Adele is a design consultant who works in product development for medical and healthcare applications. Her background is in pharma, and she has a degree in applied physiology
    Related Searches
    • Drug Discovery
    • R&D
    • Drug Development
    Suggested For You
    Mogene Mogene
    Tackling TB Resistance Tackling TB Resistance
    InSphero, Pfizer to Develop Assays for DILI InSphero, Pfizer to Develop Assays for DILI
    Could Nuts Ward Off Cancer? Could Nuts Ward Off Cancer?
    The Trials and Tribulations  of Male Contraception The Trials and Tribulations of Male Contraception
    ‘Smart’ Heparin Delivery Could Self-Modulate ‘Smart’ Heparin Delivery Could Self-Modulate
    Merus and IRB Barcelona Form Research Collaboration Merus and IRB Barcelona Form Research Collaboration
    Halozyme, Genentech in Broad Clinical Collaboration Halozyme, Genentech in Broad Clinical Collaboration
    Blackberry Wine: Could it Help Your Diabetes? Blackberry Wine: Could it Help Your Diabetes?
    Catalent Biologics Appoints R&D Director Catalent Biologics Appoints R&D Director
    Taking the Wheeze Out of Asthma Taking the Wheeze Out of Asthma
    Can Greens Cure Cancer? Can Greens Cure Cancer?
    AMRI Joins Chemical Biology Consortium AMRI Joins Chemical Biology Consortium
    How ‘Mush-room’ For Improvement in Antibiotic Production? How ‘Mush-room’ For Improvement in Antibiotic Production?
    Anyone Fancy a Beer? Anyone Fancy a Beer?

    Related Pharma Beat

    • Drug Development

      NSAIDs – Friend or Foe?

      Although widely used for years, NSAIDs have side effects that could eventually change their OTC status
      Adele Graham-King, Contributing Editor 06.06.17

    • Drug Development | Drug Discovery
      Tackling TB Resistance

      Tackling TB Resistance

      The TB Alliance is partnering with universities, government agencies, public agencies and a small number of pharma compani
      Adele Graham-King, Contributing Editor 05.09.17

    • Drug Development

      Could Nuts Ward Off Cancer?

      Recent research looks into the anti-cancer properties of various nuts
      Adele Graham-King, Contributing Editor 04.03.17


    • Drug Delivery | Drug Development | R&D

      ‘Smart’ Heparin Delivery Could Self-Modulate

      A group of researchers have spent the past two years investigating self-controlling dosing and monitoring systems
      Adele Graham-King, Contributing Editor 01.26.17

    • Drug Development | Drug Discovery | R&D

      Blackberry Wine: Could it Help Your Diabetes?

      Recent research points towards the positive impact ‘berry wine’ might have on diabetes
      Adele Graham-King, Contributing Editor 10.11.16

    • Chemistry | Drug Development
      Anyone Fancy a Beer?

      Anyone Fancy a Beer?

      The centuries-old brew continues to be investigated for its medicinal properties
      Adele Graham-King, Contributing Editor 05.05.16


    • Drug Development

      Chipping Away at the Old Cancer Block

      Advances in cancer treatment continue to march towards finding a cure
      Adele Graham-King, Contributing Editor 04.05.16

    • Clinical Trials | Drug Development

      The 3D Printed Pill

      It’s the future…or is it?
      Adele Graham-King, Contributing Editor 01.28.16

    • Clinical Trials | Drug Development | Drug Discovery | R&D

      Are We There Yet?

      Many promising cancer treatments are on the horizon
      Adele Graham-King, Contributing Editor 07.14.15


    • APIs | Bioassay Development | Drug Development | Methods Development | Process Development | Toxicology

      The Last Chance Saloon?

      Looking at the pharmaceutical ‘diet’ of anti-obesity drugs
      Adele Graham-King, Contributing Editor 06.02.15

    • Clinical Trials | Drug Development

      100 New Drugs in 10 Years?

      Repurposing drug candidates that never saw the light of day
      Adele Graham-King, Contributing Editor 03.06.15

    • APIs | Bioassay Development | Clinical Trials | Drug Development | Drug Discovery | Methods Development | Process Development | R&D | Toxicology

      Experimental Drugs

      To use or not to use unlicensed drugs? That is the question.
      Adele Graham-King, Contributing Editor 01.29.15


    • Drug Delivery | Drug Development
      The End of a Century

      The End of a Century

      Looking at 15 years of pharmaceutical evolution.
      Adele Graham-King 10.14.14

    • Drug Discovery

      Under the Sea: The Search for New Cures in the “Post-Antibiotic” Era

      A new WHO report raises some frightening questions on antimicrobial resistance, while Scotland’s PharmaSea Project looks for answers in the oceans’ depths
      Adele Graham-King 07.21.14

    • Chemistry | Drug Discovery | Supply Chain

      Toward a Process-Centered Pharma

      Saying “No” to change is normal, but adopting true QbD practices could save the industry about 20-25% of its global revenue and allow pharma to add two to three billion patients to its customer base
      Girish Malhotra, EPCOT International 06.03.14

    Trending
    • Bormioli Opens New Glass Research Center
    • Arcline Investment Acquires ChargePoint Technology
    • Spark Therapeutics Appoints CTO
    • The Future Of Vaccines And Biologics
    • BMS Expands Cell Therapy Manufacturing Capabilities
    Breaking News
    • J&J’s Single-Dose COVID-19 Vax Issued EUA
    • Icon to Acquire PRA Health Sciences
    • Phlow Corp. and USP Form Alliance
    • BMS Expands Cell Therapy Manufacturing Capabilities
    • Novo Nordisk Invests $80M in Tablet Production
    View Breaking News >
    CURRENT ISSUE

    January/February 2021

    • High Drug Loading Amorphous Solid Dispersions
    • Parenteral Drug Delivery Trends
    • Selecting the Right Outsourcing Model for Emerging Biotech
    • Inhaled Drug Delivery Technology
    • The Future of Biologics: Accelerating Production, Reducing Costs
    • Business Intelligence For (and From) the Lab
    • Communicating Your Contracting Priorities to Your Drug Company Customers
    • COVID-19 Impact Report
    • The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Martin Bauer Group Acquires Majority Stake in Beverage Company Power Brands
    Gencor Announces Positive Results in VeriSperse Bioavailability Study
    PanTheryx Inc. Acquires TruBiotics Brand from Bayer HealthCare LLC
    Coatings World

    Latest Breaking News From Coatings World

    Gelest CEO Elected to National Academy of Engineering
    PPG Appoints Tony Wu as VP, Automotive Refinish, Asia
    PPG Appoints John Bruno as VP, Investor Relations
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Axonics Buys Contura to Expand to Stress Urinary Incontinence
    Nurx Appoints Chief Medical Officer
    Median Technologies, UC San Diego to Partner on AI-Based Medical Imaging Technology
    Contract Pharma

    Latest Breaking News From Contract Pharma

    J&J’s Single-Dose COVID-19 Vax Issued EUA
    Icon to Acquire PRA Health Sciences
    Phlow Corp. and USP Form Alliance
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Universal Engraving Announces New President
    Raw Sugar Living Expands to Target with New Collection
    Supporting Female Beauty Brand Founders on International Women's Day
    Happi

    Latest Breaking News From Happi

    ACI and CBC Launch Webpage About ‘Quats’
    L’Occitane Launches Hand Cream Inspired by Women
    Kiehl’s Partners with Gyrl Wonder
    Ink World

    Latest Breaking News From Ink World

    Access Direct Mail Doubles Revenue with SCREEN's Truepress Jet520HD
    Etiflex Enters New Markets with Nilpeter FA-22 Installation
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    TLMI analyzes pandemic's effect on label industry in new report
    UEI names Ross Hutchison president
    Schreiner MediPharm and AARDEX partner for clinical trials
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    U.S. Nonwovens Rebrands as Radienz Living
    What You’re Reading on Nonwovens-Industry.com
    Texas Medical Technology Partners with My Protect Kit
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Pandemic Pain: NuVasive's 2020 Sales Fall 10 Percent
    Fusion Robotics Receives FDA Clearance for Spinal Navigation and Robotics System
    Kaia Health Unveils Next-Gen Complete MSK Care Solutions
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login